AttributesValues
type
value
  • Patients with COVID‐19 are sometimes already being treated for one or more other chronic conditions, especially if they are elderly. Introducing a treatment against COVID‐19, either on an outpatient basis or during hospitalization for more severe cases, raises the question of potential drug‐drug interactions. Here, we analyzed the potential or proven risk of the co‐administration of drugs used for the most common chronic diseases and those currently offered as treatment or undergoing therapeutic trials for COVID‐19. Practical recommendations are offered, where possible.
Subject
  • Zoonoses
  • Patient
  • Viral respiratory tract infections
  • Pharmacokinetics
  • COVID-19
  • Clinical pharmacology
  • Medical terminology
  • Occupational safety and health
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software